AGEN | tickerfilter.com

Fundamental analysis

34%

Profitability 43%

Dept financing 25%

Liquidity 28%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.26%

1 Month

68.75%

3 Months

-24.16%

6 Months

-38.78%

1 Year

-78.84%

2 Year

-91.06%

Key data

Stock price

$2.70

P/E Ratio

0.00

DAY RANGE

$2.67 - $3.00

EPS

-$10.78

52 WEEK RANGE

$1.38 - $19.69

52 WEEK CHANGE

-$78.84

MARKET CAP

64.277 M

YIELD

N/A

SHARES OUTSTANDING

21.572 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

5.79

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,742,864

AVERAGE 30 VOLUME

$770,999

Company detail

CEO: Garo H. Armen
Region: US
Website: agenusbio.com
Employees: 440
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.

AGEN - AGENUS INC